UNI-EN 18:CORRECTION-Current report 18 buy back 01032012
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| | UNI - EN REPORT No | 18 | / | 2012 | | ||||||
| Date of issue: | 2012-03-05 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| CORRECTION-Current report 18 buy back 01032012 | |||||||||||
| Official market - legal basis | |||||||||||
| Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| ACQUISITION OF OWN SHARES Current report No. 18/2012 Dated 01 March 2012 The Board of Directors of SOPHARMA AD (the “Company") hereby informs that from February 23 2012 up to and including February 29 2012 the Company bought 298 own shares representing 0.000226% of the share capital of the Company, to the total value of BGN 822.67 on the Bulgarian Stock Exchange. The average price per share was 2.76 BGN. The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010. The intention of the Company is to use the repurchased shares in the future for the purpose of providing them to shareholders of companies targeted in mergers. The total number of own shares after these transactions is 2520766, representing 1.910% of the share capital of the Company. Legal grounds: Art. 56.1 of the Act on Public Offering, Conditions Governing the Introduction of Financial Instruments to Organized Trading, and Public Companies dated 29 July 2005. Signatures of individuals authorized to represent the Company Ognian Donev | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| CORRECTION-Current report 18 buy back 01032012.doc CORRECTION-Current report 18 buy back 01032012.doc | CORRECTION-Current report 18 buy back 01032012 | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2012-03-05 | Ognian Donev | Executive Director | |||
Cena akcji Sopharma
Cena akcji Sopharma w momencie publikacji komunikatu to None PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.
